Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- CRCs Should Report All Events: SMO Seminar
November 11, 2002
- Fujisawa: Record-high Sales, Profits in 1st Half of FY2002 Marked
November 11, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 11, 2002
- Major Wholesalers' 1st-half Sales Unexpectedly Good
November 11, 2002
- Meiji Seika, Bayer to Comarket Bayclear Plus
November 11, 2002
- Freund: Sales Up 1.9%, Operating Profits Down 41.2%
November 11, 2002
- GSK, Block Drug Company (Japan) Integrated on November 1
November 11, 2002
- Health Minister Determines to Set Up Better Healthcare System
November 11, 2002
- Kuraya Sanseido Takes Over OTC Business from Heisei Yakuhin
November 11, 2002
- Korosho to Prepare Comprehensive GL for Clinical Trials
November 11, 2002
- Council to Issue Supplements QC Verification Seals
November 11, 2002
- Dear-Doctor Letter for Edaravone Issued
November 11, 2002
- BD Places Great Importance on Social Contribution: President Cohen
November 11, 2002
- Revision of Precaution for 7 Drugs Including Famotidine Instructed
November 11, 2002
- Nippon Chemiphar to Comarket Allergy Test System with Wako Pure Chemical
November 11, 2002
- Package Insert for Estrogens to Be Revised
November 11, 2002
- Sankyo to Comarket Sysmex's Influenza Test Reagent
November 11, 2002
- Chuikyo Listens to Hospital Directors on DPC System
November 11, 2002
- Korosho to Gear Up Drafting of Medical Devices Industry Vision
November 11, 2002
- MEET THE LEADERS (10)
November 11, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…